Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial (Zonegran)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00203450 |
Recruitment Status :
Completed
First Posted : September 20, 2005
Last Update Posted : September 3, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Obesity | Drug: Zonegran Drug: Placebo | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 20 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial |
Study Start Date : | May 2003 |
Actual Primary Completion Date : | March 2005 |
Actual Study Completion Date : | March 2006 |
Arm | Intervention/treatment |
---|---|
Experimental: Zonegran
Zonegran
|
Drug: Zonegran
zonisamide
Other Name: zonisamide |
Placebo Comparator: Placebo
Placebo pill
|
Drug: Placebo
Placebo pill
Other Name: placebo pill |
- The primary objective of this study is to compare the efficacy of zonisamide (Zonegran; 100mg - 400mg/day) and placebo as an adjunctive agent on lowering weight in subjects who have a body mass index (BMI) of >25 and are on a psychotropic medication with
- NThe weight loss in patients treated with Zonisamide will be significantly greater than those treated with placebo.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Are men or women, between the ages of 19 and 65, inclusive
- Have a diagnosis of any type of bipolar disorder or any type of psychotic disorder based on structured diagnostic interview (MINI).
- Are currently outpatients or inpatients and taking a neuroleptic or mood stabilizer medication (listed below) for the past 6 months, and on a stable dose for the past 2 months.
- Have a body mass index > 25.
- No substance use disorder in the past 2 months (except for nicotine or caffeine).
- Agree to not become pregnant during the study and agree to use an adequate method of birth control during the study such as a barrier method, hormonal contraceptive, or surgical sterilization (females only). All women of childbearing potential must have a negative pregnancy test before beginning study medication.
- Are able to swallow the capsules whole
- Are willing and able to follow Investigator instructions and study procedures, and report adverse events
- Not currently actively suicidal or homicidal.
- No use of topiramate within the last 6 months.
- No medical contraindication to the use of zonisamide.
List of medications for inclusion criterion #3:
All conventional neuroleptics. All atypical neuroleptics except aripiprazole or ziprasidone. All forms of valproate. All forms of lithium. All forms of carbamazepine.
Exclusion Criteria:
- Clinically significant renal or hepatic disease.
- History of acute intermittent porphyria, glucose-6phosphate dehydrogenase deficiency or hemolytic anemia.
- Allergy to zonisamide or sulfonamides.
- Have clinically unstable cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine, or other systemic disease
- Have laboratory test results that, in the opinion of the Investigator, are clinically significant abnormalities
- Require treatment with any medication (e.g., carbonic anhydrase inhibitors) that might interact adversely with, or obscure, the action of the study drug
- Are pregnant or lactating (females only)
- Have a history of nephrolithiasis
- Refuse to give informed consent
- Have previously enrolled in this study or previously been treated with zonisamide
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00203450
United States, Alabama | |
Tuscaloosa Research & Education Advancement Corporation | |
Tuscaloosa, Alabama, United States, 35404 |
Principal Investigator: | Lori L Davis, MD | Tuscaloosa Veterans Affairs Medical Center |
Responsible Party: | Lori Davis, MD, ACOS R&D, Tuscaloosa Research & Education Advancement Corporation |
ClinicalTrials.gov Identifier: | NCT00203450 |
Other Study ID Numbers: |
TREAC Zonegran for Weight Loss TREAC Zonegran for Weight Loss |
First Posted: | September 20, 2005 Key Record Dates |
Last Update Posted: | September 3, 2012 |
Last Verified: | August 2012 |
obesity zonisamide zonegran psychotropic weight gain psychotropic |
Weight Gain Body Weight Body Weight Changes Zonisamide Anticonvulsants |
Calcium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Calcium-Regulating Hormones and Agents Physiological Effects of Drugs |